Pliant Therapeutics, Inc., a biopharmaceutical company operating within the health care sector, recently disclosed its second-quarter 2026 financial results in a filing with the Securities and Exchange Commission on August 11, 2026. The company, headquartered in San Francisco, United States, is dedicated to discovering and developing novel therapies for fibrotic diseases. Pliant Therapeutics is listed on the Nasdaq stock exchange and primarily serves customers in California.
In its latest update, Pliant Therapeutics highlighted significant progress in its lead program, PLN-101095. The company is advancing its Phase 1b indication-expansion trial, “FORTIFY,” which has seen strong enrollment. This trial is a critical component of the company’s efforts to develop integrin-based therapeutics, particularly in the oncology field. To bolster its oncology initiatives, Pliant Therapeutics has appointed experienced oncology leaders to its board, aiming to enhance the strategic direction and development of its oncology arm.
Financially, the company reported a reduction in research and development and general administrative expenses compared to the same period in the previous year. This decrease is attributed to the completion of a Phase 2b/3 study and a reduction in headcount. As a result, the net loss for the quarter narrowed from the prior year, reflecting lower operating costs and modest interest income. Pliant Therapeutics reported cash and short-term investments of approximately $160 million, which management expects will sustain operations through the second half of 2028.
Despite these positive developments, the company reiterated its ongoing need to raise additional capital. This capital is essential to fund the continued development and potential commercialization of its product candidates. As of August 10, 2026, Pliant Therapeutics’ stock closed at $1.03, marking both the 52-week low and the close price for that day. The company’s market capitalization stands at approximately $65,020,000 USD, with a price-to-earnings ratio of -0.58. The 52-week high for the stock was recorded at $1.95 on October 26, 2025.
For more detailed information about Pliant Therapeutics’ activities and offerings, stakeholders and interested parties are encouraged to visit the company’s official website at www.pliantrx.com .
